|Title||Laucysteinamide A, a hybrid PKS/NRPS metabolite from a Saipan cyanobacterium, cf. Caldora penicillata|
|Publication Type||Journal Article|
|Year of Publication||2017|
|Authors||Zhang C., Naman C.B, Engene N, Gerwick WH|
|Type of Article||Article|
|Keywords||agents; blue-green alga; brine shrimp; cyanobacteria; Cytotoxicity; laucysteinamide A; lyngbya-majuscula; marine; molecular networking; natural-products; thiazoline alkaloid|
A bioactivity guided study of a cf. Caldora penicillata species, collected during a 2013 expedition to the Pacific island of Saipan, Northern Mariana Islands (a commonwealth of the USA), led to the isolation of a new thiazoline-containing alkaloid, laucysteinamide A (1). Laucysteinamide A is a new monomeric analogue of the marine cyanobacterial metabolite, somocystinamide A (2), a disulfide-bonded dimeric compound that was isolated previously from a Fijian marine cyanobacterium. The structure and absolute configuration of laucysteinamide A (1) was determined by a detailed analysis of its NMR, MS, and CD spectra. In addition, the highly bioactive lipid, curacin D (3), was also found to be present in this cyanobacterial extract. The latter compound was responsible for the potent cytotoxicity of this extract to H-460 human non-small cell lung cancer cells in vitro.
|Short Title||Mar. Drugs|